原发性胆汁性胆管炎肝移植术后预后研究现状与挑战  

Research status and challenges in the prognosis of primary biliary cholangitis after liver transplantation

作　　者：陈林[1] 刘宁[2] 金晶兰[1] 蔡艳俊[1] 许芳[1] 牛俊奇[1] 李婉玉[1] CHEN Lin;LIU Ning;JIN Jinglan;CAI Yanjun;XU Fang;NIU Junqi;LI Wanyu(Department of Hepatology,The First Hospital of Jilin University,Changchun 130021,China;Department of Cardiology,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院肝胆胰内科,长春130021 [2]吉林大学第一医院心血管疾病诊治中心,长春130021

出　　处：《临床肝胆病杂志》2021年第4期955-958,共4页Journal of Clinical Hepatology

基　　金：2018年吉林省科技发展计划项目(20180520116JH);2017年天晴肝病研究基金(TQGB20180160);2017年吉林大学第一医院交叉学科创新项目(JDYYJC006)。

摘　　要：原发性胆汁性胆管炎(PBC)是一种病因尚不明确的慢性胆汁淤积性肝病。熊去氧胆酸、奥贝胆酸等药物治疗不佳的患者最终发展为肝硬化,甚至肝衰竭。目前,肝移植是治疗PBC的唯一有效手段。主要阐述了PBC患者进行肝移植的概况、肝移植术后生存期、并发症、PBC复发以及肝移植治疗前景及挑战,为PBC移植术后的临床转归及治疗提供参考。Primary biliary cholangitis(PBC)is a chronic cholestatic liver disease with unknown etiology,and patients with poor response to ursodeoxycholic acid and obeticholic acid may eventually progress to liver cirrhosis and even liver failure.Liver transplantation is the only effective treatment method for PBC at present.This article elaborates on liver transplantation,survival time after liver transplantation,complications,recurrence of PBC after liver transplantation,and prospects and challenges of liver transplantation in patients with PBC,so as to provide a reference for clinical outcome and treatment after liver transplantation for PBC.

关 键 词：肝硬化 胆汁性 肝移植 预后 牛磺熊去氧胆酸 

分 类 号：R575.22[医药卫生—消化系统]